A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Официальное название

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

Обзор

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

Вмешательства

• Препарат Xanomeline/Trospium Chloride Capsule
  Specified dose on specified days
• Препарат Xanomeline Enteric Capsule
  Specified dose on specified days
• Препарат Placebo
  Specified dose on specified days

Первичные конечные точки

• Change from baseline on the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) total score at Week 14 [Срок оценки: At Week 14]

Вторичные конечные точки (12)

• Change from baseline on the Clinical Global Impressions-Severity (CGI-S) at Week 14 [Срок оценки: At Week 14]
• Change from baseline on CMAI-IPA Domains at Week 14 [Срок оценки: At Week 14]
• Change from baseline on CMAI Total Score at Week 14 [Срок оценки: At Week 14]
• Number of participants with Occurrence of Response at Week 14 [Срок оценки: At Week 14]
• Change from baseline on the Neuropsychiatric Inventory/Neuropsychiatric Inventory -Nursing Home (NPI/NPI-NH) Total Score at Week 14 [Срок оценки: At Week 14]
• Number of participants with Adverse Events (AEs) [Срок оценки: Up to Week 18]
• Number of participants with Treatment Emergent AEs (TEAEs) [Срок оценки: Up to Week 18]
• Number of participants with Serious AEs (SAEs) [Срок оценки: Up to Week 18]
• Number of participants with AEs leading to study drug withdrawal [Срок оценки: Up to Week 18]
• Number of deaths [Срок оценки: Up to Week 18]
• Number of participants with AEs of Special Interest (AESIs) [Срок оценки: Up to Week 18]
• Barnes Akathisia Rating Scale (BARS) [Срок оценки: Up to Week 14]

Критерии участия

Критерии включения

\- A diagnosis of Alzheimer's disease (AD) in accordance with the 2024 Alzheimer's Association criteria with one of the following confirmations of AD pathology:

i) Historical evidence of AD diagnosis with amyloid positron emission tomography (PET), Aβ42/40 ratio in CSF, pTau181/Aβ42 ratio in CSF or pTau217/Aβ42 ratio in plasma using an Health Authority (HA)-authorized diagnostic assay.

ii) If no historical evidence available:

A. A plasma biomarker will be assessed for eligibility if allowed per regulatory requirements. The test cutoff(s) will be based on diagnostic use approval.

B. If a plasma biomarker assay cannot be used or if the assay result is inconclusive, conduct one the following:

• Amyloid PET.
• Aβ42/40 ratio or pTau181/Aβ42 ratio in CSF using an HA-authorized diagnostic assay.

• Mini-Mental State Examination (MMSE) score of ≤ 24 at Screening (Visit 1).
• Have an identified caregiver who has sufficient contact (approximately 8 hours over a week) and is willing to:

i) Attend all visits and report on participant's status.

ii) Oversee participant compliance with medication and study procedures.

iii) Participate in the study assessments and provide informed consent to participate in the study.

• History of agitation that meets the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders with onset at least two weeks prior to Screening (Visit 1).
• AD participants are required to have NPI/NPI-NH Agitation/Aggression score ≥ 4 at Screening (Visit 1) and Baseline (Visit 2).
• Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) Total Score ≥ 30 at Screening (Visit 1) and Visit 2.

Критерии исключения

\- Medical Conditions.

i) Agitation symptoms that are primarily attributable to a condition other than the AD causing the dementia.

ii) History of bipolar disorder, schizophrenia, or schizoaffective disorder.

iii) History of (or at high risk for) urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the Investigator.

iv) Risk of suicidal behavior during the study as determined by the Investigator's clinical assessment and/or C-SSR.

\- Prior/Concomitant Therapy.

i) Recent history of receiving monoamine oxidase inhibitors, anticonvulsants (eg, lamotrigine, divalproex), mood stabilizers (eg, lithium), tricyclic antidepressants (eg, imipramine, desipramine), or any other psychoactive medications except for as needed anxiolytics (eg, lorazepam).

A. Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors taken at a stable dose for at least 8 weeks prior to Screening (Visit 1) may be permitted.

B. Trazodone may be used as a hypnotic or for agitation if started at least 8 weeks prior to Screening (Visit 1).

Note: Mirtazapine may be used as a hypnotic if started at least 8 weeks prior to Screening (Visit 1).

\- Other protocol-defined Inclusion/Exclusion criteria apply.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Лечение

Центры проведения

США · 43 центра

• Chandler Clinical Trials, LLC — Chandler
• Local Institution - 2631 — Chandler
• Local Institution - 2646 — Chandler
• National Institute of Clinical Research — Garden Grove
• Local Institution - 2607 — Long Beach
• Accellacare — Long Beach
• Local Institution - 2627 — Napa
• Local Institution - 2649 — Orange
• … и ещё 35 центров

Украина · 16 центров

Список центров уточняется — проверьте первичный протокол.

South Korea · 10 центров

Список центров уточняется — проверьте первичный протокол.

Великобритания · 10 центров

Список центров уточняется — проверьте первичный протокол.

Чехия · 9 центров

• AGE Centrum — Olomouc
• Neuropsychiatrie — Prague
• Institut neuropsychiatricke pece (INEP), Praha — Prague
• Neuro Health Centrum s.r.o. — Brno
• NEUROHK — Choceň
• A-SHINE s.r.o. — Pilsen
• Local Institution - 2102 — Prague
• Local Institution - 2105 — Prague
• … и ещё 1 центр

Польша · 9 центров

Список центров уточняется — проверьте первичный протокол.

Венгрия · 8 центров

• Local Institution - 2257 — Kalocsa
• Local Institution - 2250 — Győr
• Debreceni Egyetem Klinikai Kozpont — Debrecen
• Local Institution - 2254 — Gyöngyös
• Local Institution - 2256 — Budapest
• … и ещё 3 центра

Италия · 8 центров

Список центров уточняется — проверьте первичный протокол.

Аргентина · 7 центров

• Centro Neurobiológico y de Estrés Traumático - CENydET S.R.L. — Ciudad Autonoma de Buenos Aires
• Fundacion para el Estudio y Tratamiento de Enfermedades mentales- FETEM — Buenos Aires
• Local Institution - 2004 — Buenos Aires
• Instituto Modelo de Neurología, Fundación Lennox — Córdoba
• Local Institution - 2002 — Córdoba
• Instituto Médico DAMIC — Córdoba
• Resolution Psychopharmacology Research Institute — Mendoza

Франция · 7 центров

• Centre Hospitalier Universitaire Toulouse - Cité de la Santé — Toulouse
• Hôpital des Charpennes - Hospices Civils de Lyon (HCL) — Villeurbanne
• Centre Hospitalier Régional Universitaire de Lille - Hôpital Roger Salengro — Lille
• Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren — Limoges
• Hopital Gui Chauliac - Chu Montpellier — Montpellier
• Centres Memoire de Ressources et de Recherche (CMRR) - Hopital Lariboisiere-Fernand-Widal — Paris
• Les Hôpitaux Universitaires de Strasbourg - Hôpital de la Robertsau — Strasbourg

Чили · 6 центров

• Biomedica Research Group — Santiago
• Local Institution - 2050 — Santiago
• Pontificia Universidad Catolica de Chile — Santiago
• Clinica Alemana — Vitacura
• Local Institution - 2055 — Viña del Mar
• Psicomed Estudios Médicos Cía Ltda — Antofagasta

Израиль · 5 центров

Список центров уточняется — проверьте первичный протокол.

Пуэрто-Рико · 4 центра

Список центров уточняется — проверьте первичный протокол.

Германия · 3 центра

• Local Institution - 2201 — Düsseldorf
• Local Institution - 2205 — Halle
• Local Institution - 2206 — Westerstede

Идентификаторы

NCT: NCT07011745 · CN012-0024 · 2025-520612-34 · U1111-1316-5827

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗